39.90
+0.8(+2.05%)
Currency In USD
Address
7 Golda Meir Street
Ness Ziona, 7403650
Israel
Phone
972 8 931 3433
Website
Sector
Healthcare
Industry
Biotechnology
Employees
34
First IPO Date
February 01, 2018
| Name | Title | Pay | Year Born |
| Mr. Moshe Arkin | Chief Executive Officer & Executive Chairman | 0 | 1953 |
| Dr. Itzik Yosef | Chief Operating Officer | 236,000 | 1976 |
| Ms. Tamar Fishman Jutkowitz | Vice President & General Counsel | 271,000 | 1976 |
| Mr. Eyal Ben-Or | Chief Financial Officer | 0 | 1983 |
| Mr. Michael Glezin | Chief Business Officer | 0 | 1982 |
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.